411 related articles for article (PubMed ID: 25229770)
21. Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma.
Slatter TL; Hsia H; Samaranayaka A; Sykes P; Clow WB; Devenish CJ; Sutton T; Royds JA; Ip PP; Cheung AN; Hung NA
J Pathol Clin Res; 2015 Apr; 1(2):95-105. PubMed ID: 27499896
[TBL] [Abstract][Full Text] [Related]
22. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
[TBL] [Abstract][Full Text] [Related]
23. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
24. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
25. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
26. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
27. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
28. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.
Nguyen DN; Heaphy CM; de Wilde RF; Orr BA; Odia Y; Eberhart CG; Meeker AK; Rodriguez FJ
Brain Pathol; 2013 May; 23(3):237-43. PubMed ID: 22928601
[TBL] [Abstract][Full Text] [Related]
29. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
[TBL] [Abstract][Full Text] [Related]
30. Altered telomeres in tumors with ATRX and DAXX mutations.
Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
[TBL] [Abstract][Full Text] [Related]
32. Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells.
Eid R; Demattei MV; Episkopou H; Augé-Gouillou C; Decottignies A; Grandin N; Charbonneau M
Mol Cell Biol; 2015 Aug; 35(16):2818-30. PubMed ID: 26055325
[TBL] [Abstract][Full Text] [Related]
33. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
[TBL] [Abstract][Full Text] [Related]
34. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
[TBL] [Abstract][Full Text] [Related]
35. Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance.
Tang M; Li Y; Zhang Y; Chen Y; Huang W; Wang D; Zaug AJ; Liu D; Zhao Y; Cech TR; Ma W; Songyang Z
J Cell Sci; 2015 Jan; 128(2):331-41. PubMed ID: 25416818
[TBL] [Abstract][Full Text] [Related]
36. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
37. Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.
Yang CY; Liau JY; Huang WJ; Chang YT; Chang MC; Lee JC; Tsai JH; Su YN; Hung CC; Jeng YM
Am J Transl Res; 2015; 7(10):2072-81. PubMed ID: 26692951
[TBL] [Abstract][Full Text] [Related]
38. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.
Mangerel J; Price A; Castelo-Branco P; Brzezinski J; Buczkowicz P; Rakopoulos P; Merino D; Baskin B; Wasserman J; Mistry M; Barszczyk M; Picard D; Mack S; Remke M; Starkman H; Elizabeth C; Zhang C; Alon N; Lees J; Andrulis IL; Wunder JS; Jabado N; Johnston DL; Rutka JT; Dirks PB; Bouffet E; Taylor MD; Huang A; Malkin D; Hawkins C; Tabori U
Acta Neuropathol; 2014 Dec; 128(6):853-62. PubMed ID: 25315281
[TBL] [Abstract][Full Text] [Related]
39. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations are a rare event in gastrointestinal stromal tumors.
Akaike K; Toda-Ishii M; Suehara Y; Mukaihara K; Kubota D; Mitani K; Takagi T; Kaneko K; Yao T; Saito T
Springerplus; 2015; 4():836. PubMed ID: 26753123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]